SCHEMBL4119062

SCHEMBL4119062

O=C(Nc1ccc(OC(F)F)cc1)Nc1ccc(C(=O)c2ccccc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.56
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
HTT P42858 3/20 0.56
LMNA P02545 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
STING1 Q86WV6 1/20 0.56
ALDH1A1 P00352 8/20 0.54
TSHR P16473 1/20 0.53
RAB9A P51151 3/20 0.53
NPC1 O15118 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.51
HPGD P15428 3/20 0.51
TEAD4 Q15561 1/20 0.51
CRHBP P24387 2/20 0.51
CRHR2 Q13324 2/20 0.51
ALOX15 P16050 1/20 0.50
GFER P55789 1/20 0.50
ADAM17 P78536 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4111928 0.89 MAPT (0.68) MAPTMEN1KMT2AHTTLMNA
SCHEMBL7266265 0.87 MAPT (0.60) MAPTMEN1KMT2ALMNAALDH1A1
SCHEMBL4118525 0.86 EPHX2 (0.58) MAPTMEN1KMT2AHTTLMNA
SCHEMBL4118526 0.86 MAPT (0.66) MAPTMEN1KMT2AHTTLMNA
SCHEMBL4124133 0.85 MAPT (0.59) MAPTMEN1KMT2AHTTLMNA
SCHEMBL4116853 0.85 MAPT (0.62) MAPTMEN1KMT2AHTTLMNA
SCHEMBL30455793 0.83 PGR (0.66) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL4117708 0.82 ALDH1A1 (0.61) MAPTMEN1KMT2AHTTLMNA
SCHEMBL4116664 0.82 SMN1; SMN2 (0.67) MAPTMEN1KMT2AHTTLMNA
Urea SCHEMBL4110289 0.81 MAPT (0.61) MAPTMEN1KMT2AHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 MAPT 1654/4885MEN1 3273/4885KMT2A 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.